Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ormonde Mining acquires stake in Peak Nickel

Tue, 07th Feb 2023 19:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Haydale Graphene Industries PLC - Ammanford, Wales-based graphene technology company - Says that its "bespoke" mechanical graphene is used to create kayaks for Norse Kayaks. Adds that the Norse kayak is 30% lighter to 16 kilogrammes from 23kg. "The use of graphene has exceeded our expectations and we are sure that this will set a new standard of what is possible to do with a sea kayak. We have never seen this kind of impact strength on light weight sea kayaks in our 20 years' experience in the kayaking business," Norse founder Kjetil Sandvik says.

----------

Tekcapital PLC - London-based intellectual property investor - Launches its Lucyd Lyte 2.0 eyewear. Intends to introduce the product to optical and speciality retail chains worldwide. Notes that it is a "major upgrade" to its flagship Lucyd Lyte audio eyewear platform.

----------

Witan Investment Trust PLC - investment firm - Declares a fourth interim dividend of 1.60p per ordinary share, taking it total dividends for 2022 to 5.80p. Intend to grow its dividend "in real terms," ahead of inflation. Notes that its dividends have grown "substantially" ahead of UK inflation over the past 5 and 10 years.

----------

Ormonde Mining PLC - cash shell, former Dublin-based mineral resource company - Is temporarily suspended from trading on AIM on Wednesday, "pending an announcement and publication of an admission document." Explains that it became a cash shell in October 2022 and was therefore required to announce an acquisition or acquisitions that would be a reverse takeover. Says that it acquired a 20% stake in Peak Nickel Ltd for GBP450,000. Adds that it was granted an option to invest a further GBP4 million in cash in PNL, taking its stake to 49.9% and to buy the remaining 80% of PLN through the issue of Ormonde ordinary shares. Notes that this option can be exercised following the completion of the initial work programme. Notes that the exercise will be dependent on the results of the work programme, among other things, but satisfy the AIM Rule 14 conditions in relation to being a cash shell.

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Files four new patent applications to protect "innovations" around novel gene targets, associated disease-relevant biology and proprietary siRNA stabilisation chemistries. siRNA is short for small interfering RNA. Notes that the new applications build on a period of IP generation in 2022, where a series of patent applications were filed to protect 13 inventions. "This latest announcement of patent filings reflects our continued pace of innovation and progress towards an in-house pipeline of first-in-class RNAi candidates derived from our computational platform. We will continue to build on this progress, maintain the momentum of invention and actively protect our expanding intellectual property portfolio," CEO Ali Mortazavi comments.

----------

Lok'n Store Group PLC - Hampshire, England-based self-storage - Says that its board approved a transition for its shares on AIM to the Stock Exchange Electronic Trading System platform from the London Stock Exchange's Stock Exchange Electronic Trading Service. The move was effective from February 7. Explains that the move is supposed to provide investors with access to the entire SETS system, "providing liquidity via traditional order book trades, as well as firm two-way quotes from market makers."

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
29 Jun 2010 16:00

UK SMALLCAP ROUNDUP: E-Therapeutics Seeks Pharma Alliances

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps E-THERAPEUTICS PLC (ETX.LN), a U.K. drug developer, said Tuesday its focus this year and next will be on clinical trials of its experimental medicines an

Read more
29 Jun 2010 12:06

INTERVIEW: E-Therapeutics Readies Trials, Seeks Alliances

By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--U.K. drug developer e-Therapeutics PLC (ETX.LN) Tuesday said its focus this year and next will be on clinical trials of its experimental medicines and securing alliances with pharmaceutical companies. E-Therapeutics, which uses

Read more
29 Jun 2010 11:03

Small caps round-up: Northern Bear, Airsprung, Pursuit Dynamics...

Support services group Northern Bear stretched its strong run Tuesday after claiming a good start to the new financial year, with its order book and pipeline well up on a year ago. "The board is pleased to announce that the new financial year has started well, with strong order books and a healthy

Read more
29 Jun 2010 08:01

E-Therapeutics Loss Widens; In Talks With Drug Makers

LONDON (Dow Jones)--Drug discovery company e-Therapeutics PLC (ETX.LN) Tuesday reported a wider fiscal-year loss and said it remains in talks with drug makers about commercial collaborations. E-Therapeutics, which uses computer software to develop new drugs, added the first of several planned Ph

Read more
2 Mar 2010 16:33

Chairman's wife buys Redrow shares

Redrow chairman Steve Morgan's wife has bought 100,000 shares in the housebuilder taking their combined stake to 29.95%. Fiona Morgan paid 131.5p a share for the 100,000 shares. The total cost was £131,500. Morgan founded Redrow in 1974 and floated the company 20 years later. He also owns Wolver

Read more
27 Jul 2009 08:38

e-Therapeutics narrows losses

Drug discovery and development company e-Therapeutics said annual losses narrowed and it remains confident of becoming cash generative. For the year ended 31 January loss before tax narrowed to £1.96m from a loss of £2.2m the year before. Revenue increased to £67,000 from £64,000 the previous year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.